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terms of choice of treatment strategy for longterm treatment of
gastroesophageal reﬂux disease and the associated costs.
METHODS: This study is a follow-up study to the Nexium One
study and is an open observational study in a general practice
setting with 1206 patients. This study was designed as a natu-
ralistic study to emulate a real-life situation as closely as possi-
ble. The observational period was six-months. Three groups of
patients were included in to this study: 1) patients who partici-
pated in the Nexium One trial and were included by general
practionernes (GPs), who participated in the Nexium One trial;
2) patients who did not participate in the Nexium One trial and
were included by GPs, who participated in the Nexium One trial;
and 3) patients who did not participate in the Nexium One trial
and were included by GPs, who did not participate in the
Nexium One trial. As to whether the randomised Nexium One
study reﬂected real-life in terms of treatment and associated
costs, this was investigated by comparing direct medical costs,
total costs for the following patients: A) all patients from the
Nexium One study and B) group three patients (see above).
RESULTS/CONCLUSIONS: A signiﬁcant difference was found
in total costs between group three and all the patients in the
Nexium One study. However, there was no signiﬁcant difference
in direct medical costs. In other words, the Nexium One study
reﬂects real-life costs as there is no difference in the costs of treat-
ment between all patients in the Nexium One study and the
patients, who did not participate in the Nexium One study and
were included by GPs who did not participate in the Nexium
One study.
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OBJECTIVES: To assess the validity and subject acceptability of
electronic data capture (EDC) versions of Irritable Bowel Syn-
drome Quality of Life(IBS-QOL), EuroQoL(EQ-5D) and Work
Productivity and Activity Impairment (WPAI:IBS) question-
naires. METHODS: Comparability of EDC and paper question-
naires was evaluated in 72 subjects with IBS who completed a
baseline EDC or paper questionnaire, a crossover questionnaire
24 hours later, and a retest of the crossover version at week-one.
The EDC version was presented on a hand-held device. Compa-
rability was assessed using paired t-test statistics, intraclass cor-
relation coefﬁcients (ICC) and tests for internal consistency
(Cronbach’s alpha). RESULTS: No signiﬁcant differences were
found between scores obtained by paper questionnaire and EDC
at the baseline and crossover assessments. ICCs between base-
line and crossover assessments ranged from 0.83 to 0.96 for the
IBS-QOL scores, 0.82 to 0.96 for the WPAI:IBS scores, and 0.77
to 0.82 for the EQ-5D. Internal consistency was comparable for
the two data collection methods for the IBS-QOL overall score
(0.96) and subscales and the EQ-5D Index (0.70 vs. 0.74). Retest
statistics (ICC) were generally comparable between the EDC and
paper versions for all scores, as was the relationship between
scores and levels of IBS symptom severity. Ease of use was com-
parable for the two modes of administration, but more patients
preferred EDC (47.2%) than the paper questionnaire (23.6%).
CONCLUSIONS: EDC versions of the IBS-QOL, EQ-5D, and
WPAI:IBS are comparable to paper questionnaires in terms of
internal consistency, test-retest reliability, and discriminant valid-
ity and have greater patient acceptability.
PGI16
HEALTH RELATED QUALITY OF LIFE CHANGES IN
LAMIVUDINE REFRACTORY CHRONIC HEPATITIS B (CHB)
PATIENTS AFTER ENTECAVIR (ETV) OR LAMIVUDINE (LAM)
TREATMENT¡V BMS STUDY 026
Su J1, Chen L1, Iloeje U1, Cross A1, Hindes R1,Wilber R1, Johnson J2
1Bristol-Myers Squibb, Wallingford, CT, USA; 2University of Alberta,
Edmonton, AB, Canada
The impact of treatment on health related quality of life
(HRQoL) in CHB patients is unclear. OBJECTIVE: The objec-
tive of this study was to compare the changes in HRQoL from
baseline, as measured by changes in health status using the
EuroQoL 5 Dimensions (EQ-5D) questionnaire, in patients
receiving ETV or LAM treatment. Utility scores are anchored
between full health (1) and death (0). METHODS: This was a
randomized double blind, double dummy, active controlled trial.
Questionnaires were administered prior to the physician visit at
baseline, Weeks 24 and 48. Mean changes in health index score
(HIS) and visual analog scale (VAS) score from baseline were cal-
culated in all treated patients. Proportions of patients who had
improvement or no change in health dimensions were compared
between the two treatment groups, and patients with missing
Week-48 data were considered failures (NC = F). RESULTS: A
total of 116 of 141 (82%) ETV and 114 of 145 (79%) LAM
patients completed the questionnaires at baseline. Though ETV
patients demonstrated a clinically meaningful improvement in
HIS (0.03) and LAM patients did not (0.01), the difference (0.02)
was not statistically signiﬁcant (p = 0.12). ETV patients had a
trend towards better change in VAS at Week-48 (ETV = 4.13;
LAM = 0.91; mean difference estimate ETV-LAM = 2.11; p =
0.21). A larger proportion of ETV patients had improvement or
no change in all ﬁve health dimensions at Week-48. ETV treat-
ment was superior to LAM in the following dimensions: mobil-
ity; self care; pain or discomfort (94% vs. 82%, p = 0.007; 94%
vs. 85%, p = 0.03; and 90% vs. 77%, p = 0.01, respectively).
CONCLUSION: ETV therapy was associated with greater pro-
portions of patients with improvement or no change in mobil-
ity, self care, and pain or discomfort after 48-weeks of treatment.
ETV patients demonstrated a clinically meaningful improvement
in HIS, and greater improvement in VAS from baseline compared
to LAM.
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OBJECTIVES: To evaluate the impact of tegaserod 6mg b.i.d.
on the quality of life (QoL) of men and women with IBS-C, as
deﬁned by Rome II criteria. METHODS: A multicenter, open-
label, prospective, single-cohort study was conducted in Spain.
Patients entered a one-month, treatment-free, baseline period fol-
lowed by three months’ treatment with tegaserod 6mg b.i.d. and
subsequently, a one-month withdrawal period (no treatment).
QoL was assessed at the end of baseline, treatment and with-
drawal periods using the IBS-QOL; a validated modiﬁed disease-
speciﬁc instrument and the SF-36; a validated generic instrument.
Patients recorded their level of IBS symptom relief in a weekly
diary. Patients were considered responders (R) if ≥two-weeks’
satisfactory relief of global IBS-C symptoms was experienced
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during the last month of treatment. RESULTS: Of 167 patients
(20 men, 147 women; mean age 43.5 years) included in the
analysis, 72% responded to tegaserod. At baseline, SF-36 scores
from IBS-C patients were lower than those from the general pop-
ulation, but increased in all dimensions with treatment (p =
0.0068 for General Health), reaching values similar to those of
the general population. An increase in all SF-36 dimensions was
observed in responders (R), whereas a decrease occurred in non-
responders (NR, General Health dimension p = 0.004). IBS-QOL
scores (from baseline to treatment) signiﬁcantly increased in all
dimensions (p < 0.0001 for overall assessment). The mean incre-
ment in IBS-QOL was greater for R than NR (Overall dimen-
sion, p < 0.05). Upon treatment withdrawal, some dimensions
of SF-36 and IBS-QOL scores decreased but did not return to
pretreatment levels. CONCLUSIONS: QoL is impaired in IBS-C
patients. Treatment with tegaserod 6mg b.i.d. improves QoL in
patients with IBS-C to a level almost equivalent to that of the
general population, and deterioration in QoL occurs upon treat-
ment discontinuation.
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OBJECTIVE: To assess completeness of safety reporting in pub-
lished clinical trials, including use of incidence, severity, and rela-
tionship to drug thresholds for listing of speciﬁc adverse events
(AEs). METHODS: We used data from previously conducted
systematic reviews in three areas: treatment of rheumatoid
arthritis (RA) with disease-modifying anti-rheumatic drugs (168
studies, 1969–2001); treatment of migraine with 5HT-1 agonists
(38 studies, 1991–2003); and anti-neoplastic treatment of
relapsed or refractory non-Hodgkin’s lymphoma (NHL) (27
studies, 1991–2003). The type of safety reporting for each study
was appraised by two reviewers. RESULTS: Only a minority of
studies in each of the clinical areas presented a complete listing
of all AEs occuring during the trial (RA 17%, migraine 8%,
NHL 30%); a substantial number (10–25%) had no safety data
extractable. Among studies with partial AE reporting the thresh-
olds used varied by clinical setting: two-thirds of RA and NHL
studies with a reporting threshold used the author- or investiga-
tor-attributed relationship to drug to determine which AEs
would be listed in published reports, while 71% of migraine
studies with a threshold used incidence (e.g. only AEs occuring
in more than 5% of patients were listed). The severity threshold
(reporting of only serious AEs or only grade 3–4 AEs) was the
least common in all three clinical areas examined. No consistent
relationship was found between complete AE reporting and
study sponsorship (industry vs. non-industry/not reported) or
year published (pre vs. post 1995). Smaller studies (<100
patients) were more likely to contain complete AE reporting,
perhaps due to the difﬁculty of providing a comprehensive listing
of all events in larger studies. CONCLUSIONS: Incidence and
relationship to drug remain common thresholds for AE report-
ing in published clinical trials. Early detection of rare or unan-
ticipated events by meta-analysis of published trial data is thus
made more challenging.
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Genetic test technologies offer hope for early diagnosis and iden-
tiﬁcation of persons at risk for serious diseases. Because many of
these tests are costly and applicable to large populations, evalu-
ations of the cost-effectiveness of these technologies are impor-
tant. OBJECTIVES: To conduct a systematic search for and
review of economic evaluations of genetic testing technologies.
METHODS: PubMed, Proquest, LexisNexis, Expanded 
Academic Index, The Harvard Review of Economic Analyses,
PsyclINFO, NICE and CCOHTA databases were searched for
original cost-effectiveness articles published from 1990 to
present. MESH terms included: economic(s) and/or cost(s),
genetic, gene, and/or genotype. Selection criteria included genetic
tests for genetic conditions, deﬁned as analysis of human DNA,
RNA, chromosomes, proteins, and certain metabolites in order
to detect heritable disease-related genotypes, mutations, pheno-
types or karyotypes for clinical purposes. Articles were catego-
rized by clinical category and type of economic study (e.g.,
cost-utility, cost-beneﬁt), then graded independently by the
authors using CEA study quality system developed by Chiou et
al (Med Care, 2003;41:32). RESULTS: A total of 149 abstracts
were retrieved using the search terms; 63 met selection criteria.
Types of economic studies were as follows, cost-utility (25%);
cost-beneﬁt (19%); cost-minimization (6%); cost-effectiveness
(59%). Clinical testing categories were as follows: preconception
carrier (8%); prenatal diagnosis (40%); adult (57%). The studies
involved 26 different medical conditions. Study quality ranged
from 43–100 (average 82). Cost-utility studies were of highest
quality (mean 91); cost-minimization studies were of lowest
quality (mean 63). Adult studies had the highest rating (mean
86); preconception testing studies were lowest in quality (mean
74). Intraclass correlation among raters was 0.82 (CI 0.70–0.89).
CONCLUSIONS: A number of economic analyses have been
published in human genetics across a wide range of conditions.
Study quality varied widely. Priority areas for the ﬁeld include
increasing quality and uniformity of measures of outcome.
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OBJECTIVES: The purpose of this study was to evaluate the
effects of using Duan’s mean anti-logged residuals (mean smear-
ing estimator) or a median smearing estimator with positively
skewed distributions on predicting costs. METHODS: Data for
this study came from managed care pharmacy and medical
records containing drug-drug interactions (DDIs) from January
1, 1997 to December 31, 1999. Two matched cohort groups
were studied. DDI cases were identiﬁed as receiving medications
involving monoamine oxidase inhibitor (MAOIs) or anti-
coagulant DDIs. Controls were age and sex matched to cases.
Costs were positively skewed and were then natural log trans-
formed as the dependent variable in regression models. The
retransformed costs employing the mean and median smearing
estimators, respectively, were compared. Model ﬁt was assessed
using mean squared error (MSE) for both mean and median
smearing estimators. RESULTS: A total of 156 and 5754 sub-
jects were identiﬁed as MAOI and anti-coagulant groups, respec-
